Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the N-terminus
The protein has a calculated MW of 23.9 kDa. The protein migrates as 22-25 kDa under reducing (R) condition (SDS-PAGE).
>95% as determined by SDS-PAGE.
Supplied as 0.2 μm filtered solution in 20 mM Tris, 250 mM NaCl, pH8.5 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
SARS-CoV-2 NSP8, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Atilotrelvir/Ritonavir | Approved | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 泰中定 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 2023-11-23 | Coronavirus Disease 2019 (COVID-19) | Details | |
Simnotrelvir | SIM-0417; SSD-8432; VV-934 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19) | Details | |
Leritrelvir | RAY-1216; [14C]RAY1216; [14C]-RAY-1216 | Approved | Guangdong Raynovent Biotech Co Ltd | 乐睿灵 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Guangdong Raynovent Biotech Co Ltd | 2023-03-23 | Coronavirus Disease 2019 (COVID-19); Acute Kidney Injury; Hepatic Insufficiency | Details |
Simnotrelvir/Ritonavir | SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir | Approved | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Jiangsu Simcere Pharmaceutical Co Ltd, Wuhan Institute Of Virology, Chinese Academy Of Sciences | 先诺欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Renal Insufficiency; Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency | Details |
Ensitrelvir Fumaric Acid | S-217622 | Approved | Shionogi & Co Ltd, Hokkaido University | Xocova | Japan | Coronavirus Disease 2019 (COVID-19) | Shionogi & Co Ltd | 2022-11-22 | Renal Insufficiency; Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency | Details |
Nirmatrelvir/Ritonavir | Approved | Pfizer Inc | Paxlovid | EU | Coronavirus Disease 2019 (COVID-19) | Pfizer Europe Ma Eeig | 2022-01-28 | Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ebselen | SPI-1005; SPI-3005; PZ-51; DR-3305 | Phase 3 Clinical | Sound Pharmaceuticals Inc, Daiichi Sankyo Co Ltd | Tinnitus; Diabetes Mellitus, Type 1; Head and Neck Neoplasms; Diabetes Mellitus, Type 2; Ototoxicity; Neoplasms; Bipolar Disorder; Coronavirus Disease 2019 (COVID-19); Hearing Loss; Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Lung Neoplasms; Nervous System Diseases; Hearing Loss, Noise-Induced; Meniere Disease | Details |
Olgotrelvir | STI1558; STI-1558 | Phase 3 Clinical | Texas A&M University | Coronavirus Disease 2019 (COVID-19) | Details |
S-892216 | S-892216 | Phase 3 Clinical | Shionogi & Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
ibuzatrelvir | PF-07817883 | Phase 3 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Mprosevir | WPV-01 | Phase 3 Clinical | Westlake University | Coronavirus Disease 2019 (COVID-19) | Details |
QLS-1128 | QLS-1128 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
MIR-19 | MIR-19 | Phase 3 Clinical | St. Petersburg Scientific Research Institute of Vaccines and Sera | Coronavirus Disease 2019 (COVID-19) | Details |
Bofutrelvir | FB-2001; DC-402234 | Phase 3 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Frontier Biotechnologies Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Nirmatrelvir | PF-07321332 | Phase 3 Clinical | Pfizer As | Coronavirus Disease 2019 (COVID-19); Post-Acute COVID-19 Syndrome; Hepatic Insufficiency | Details |
Deusitrelvir | SHEN-211; SHEN211 | Phase 2 Clinical | Hubei JKT BioPharma Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
HS-10517 | HS-10517; HS10517 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
EDP-235 | EDP-235 | Phase 2 Clinical | Enanta Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Tollovir | Phase 2 Clinical | Todos Medical Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
Pentarlandir | SNB-01; SNB-011 | Phase 2 Clinical | Syneurx International (Taiwan) Corp | Coronavirus Disease 2019 (COVID-19) | Details |
CDI-988 | CDI988 | Phase 1 Clinical | Cocrystal Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Pomotrelvir | PBI-0451 | Phase 1 Clinical | Pardes Biosciences Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Travatrelvir | 83-0060; TRX-01 | Phase 1 Clinical | Traws Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
CMX-990 | CMX-990; CMX990 | Phase 1 Clinical | The Scripps Research Institute Inc | Coronavirus Disease 2019 (COVID-19) | Details |
WPV-02 | WPV-02; WPV02 | Phase 1 Clinical | Westlake Pharmaceuticals (Hangzhou) Co Ltd | Virus Diseases | Details |
ISM-3312 | ISM-3312 | Phase 1 Clinical | Insilico Medicine Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
ABBV-903 | ABBV-903 | Phase 1 Clinical | Abbvie Inc | Details | |
SYH-2055 | SYH-2055 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Atilotrelvir | GST-HG171 | Phase 1 Clinical | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
ALG-097558 | ALG-097558 | Phase 1 Clinical | Rega Institute, Ku Leuven, Aligos Therapeutics Inc | Coronavirus Disease 2019 (COVID-19) | Details |
ASC11 | ASC-11 | Phase 1 Clinical | Ascletis Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
Lufotrelvir | PF-07304814 | Phase 1 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Virus Diseases | Details |
GS221 | GS-221; GS221 | Clinical | Grand Pharmaceutical (China) Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
This web search service is supported by Google Inc.